In-vitro in-vivo correlation models for glibenclamide after administration of metformin/glibenclamide tablets to healthy human volunteers

被引:20
|
作者
Balan, G
Timmins, P
Greene, DS
Marathe, PH
机构
[1] Bristol Myers Squibb Co, Dept Metab & Pharmacokinet, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Co, Dept Biopharmaceut, Moreton CH46 1QW, England
关键词
D O I
10.1211/0022357001774688
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study, level C and A in-vitro in-vivo correlation (IVIVC) models were developed for glibenclamide. In-vitro dissolution data were collected for the glibenclamide component of three metformin/glibenclamide tablets using a USP Type II apparatus. In-vivo plasma concentration data were obtained after administration of the prototype formulations to 24 healthy volunteers and subject to deconvolution analysis to obtain percentage in-vivo absorbed profiles. Multiple linear level C models were developed for CMAX and AUC(0-48) using percentage in-vitro dissolved data at 10, 45 and 120 min. Initially, the level A model was constructed for the first 2 h only, based on availability of in-vitro data. Another level A model was attempted using a time-scaled approach, with percentage in-vivo absorbed at time t and percentage in-vitro dissolved at time t/I as the correlating data. Internal predictability was evaluated for the level C and time-scaled level A models. For all level C approaches, linear regression models with r(2) > 0.99 were determined. The prediction errors (% PE) for C-max and AUC((0-48)) were less than 1% for all formulations at all three chosen time points. The deconvolution analysis indicated biphasic absorption for glibenclamide, with one phase occurring at 2-3 h and another at 6-12 h after dose administration. The level A model using 2-h data was not unique for all formulations and was therefore not developed. The time-scaling factor I correlated highly (r(2) = 0.99) with in vitro mean dissolution time (MDT). A linear regression time scaled model (r(2) = 0.97) was successfully developed using in-vitro and in-vivo data from all 3 formulations. However, the internal predictability of the time-scaled model was poor, with % PE values for C-max and AUC((0-48)) being as much as 30.5% and 18.7%, respectively. The results indicate that level C models have good internal predictability. Though a time-scaled level A IVIVC model was successfully developed, the model was found to have poor internal predictability.
引用
收藏
页码:831 / 838
页数:8
相关论文
共 50 条
  • [1] INVESTIGATION INTO THE DIFFERENTIAL ANTAGONISM OF RELAXIN BY GLIBENCLAMIDE IN-VIVO VS IN-VITRO IN THE RAT UTERUS
    HUGHES, SJ
    HOLLINGSWORTH, M
    BRITISH JOURNAL OF PHARMACOLOGY, 1994, 111 : P246 - P246
  • [2] In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers
    Balan, G
    Timmins, P
    Greene, DS
    Marathe, PH
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (08) : 1176 - 1185
  • [3] PREPARATION, IN-VITRO AND IN-VIVO CHARACTERIZATION OF TRANSDERMAL PATCH CONTAINING GLIBENCLAMIDE AND ATENOLOL: A COMBINATIONAL APPROACH
    Anitha, Posina
    Ramkanth, Sundarapandiyan
    Saleem, Mohamed T. S.
    Umasankari, Kommireddy
    Reddy, Boddu Praveen
    Chetty, Madhusudhana
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 24 (02) : 155 - 163
  • [4] IN-VITRO - IN-VIVO CORRELATION AND AGING STUDIES OF COMMERCIAL HYDROCHLOROTHIAZIDE TABLETS
    HOSSIE, RD
    MATTOK, GL
    MCGILVERAY, IJ
    REVUE CANADIENNE DE BIOLOGIE, 1973, 32 : 85 - 89
  • [5] CARDIAC EFFECT OF GLIBENCLAMIDE IN-VITRO AND IN-VIVO - A COMPARISON WITH COMPOUNDS RELATED TO AZ-DF-265
    LIGHTBOWN, ID
    COOPER, S
    LAD, N
    MACKENZIE, I
    BRITISH JOURNAL OF PHARMACOLOGY, 1994, 112 : U19 - U19
  • [6] INFLUENCE OF GLIBENCLAMIDE ON PATTERN OF METABOLITES IN LIVER OF NORMAL RATS AND RATS WITH ALLOXAN DIABETES BOTH IN-VIVO AND IN-VITRO
    RUDORFF, KH
    PORR, M
    MITZKAT, HJ
    ACTA DIABETOLOGICA LATINA, 1973, 10 (01): : 155 - 155
  • [7] In-vitro and in-vivo correlation for two gliclazide extended-release tablets
    Mandal, U.
    Ray, K. K.
    Gowda, Veeran
    Ghosh, A.
    Pal, T. K.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (07) : 971 - 976
  • [8] DUODENAL INSULIN-RELEASING ACTIVITY (DIRA) IN BLOOD OF HEALTHY VOLUNTEERS AFTER ORAL-ADMINISTRATION OF GLIBENCLAMIDE
    ZERMATTEN, A
    HEPTNER, W
    ENZMANN, F
    FELBER, JP
    DIABETOLOGIA, 1977, 13 (04) : 441 - 441
  • [9] Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma
    de Souza Neto, Fernando P.
    Bernardes, Sara S.
    Marinello, Poliana C.
    Melo, Gabriella P.
    Luiz, Rodrigo C.
    Cecchini, Rubens
    Cecchini, Alessandra L.
    MELANOMA RESEARCH, 2017, 27 (06) : 536 - 544
  • [10] HUMAN MODELS FOR IN-VIVO AND IN-VITRO ASSESSMENT OF TOPICAL ANTIFUNGAL COMPOUNDS
    KNIGHT, AG
    BRITISH JOURNAL OF DERMATOLOGY, 1973, 89 (05) : 509 - 514